The FI quantifies overall health status in people with scleroderma and predicts mortality and it might help with decisions about who might best be served by more aggressive treatment, such as bone marrow transplantation. PubMed, J Rheumatol, 03/01/2014. (Also see: Systemic Scleroderma: Prognosis and Mortality)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.